Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adaptive Biotechnologies files detailed disclosures that reveal the financial dynamics of building a commercial diagnostics business alongside research partnerships. For investors analyzing ADPT, the 10-K and 10-Q filings break down revenue between MRD diagnostic testing and immune medicine research collaborations, showing how each segment contributes to overall performance.
The company's quarterly reports contain data on clonoSEQ test volumes, a key operational metric that indicates commercial adoption of its diagnostic platform. Research and development spending details show investments in expanding the platform's clinical applications, while partnership revenue recognition patterns reflect the milestone-based nature of pharmaceutical collaborations.
Form 4 insider transaction filings track executive and director trading activity. For a biotech company with significant equity compensation, monitoring these transactions provides insight into how leadership views the company's prospects.
Our AI-powered analysis highlights the most relevant disclosures in Adaptive's SEC filings, making it easier to understand complex biotech accounting without reading hundreds of pages. Track revenue segment trends, cash runway, and partnership milestones all in one place.
- Revenue breakdown between diagnostics and research partnerships
- clonoSEQ test volume trends and reimbursement updates
- R&D spending on new diagnostic applications
- Insider buying and selling through Form 4 filings
- Material events via 8-K filings including FDA decisions
Adaptive Biotechnologies Corp’s Chief People Officer reported stock option exercises and a share sale. On December 15, 2025, the officer exercised options to acquire a total of 97,022 shares of common stock at exercise prices of
Adaptive Biotechnologies director Robert Hershberg reported an open-market sale of company stock. On 12/10/2025, he sold 22,968 shares of Adaptive Biotechnologies common stock at a price of $16 per share.
Following this transaction, Hershberg now beneficially owns 46,722 shares of Adaptive Biotechnologies common stock, held directly. The filing identifies him as a director of the company and shows that the report was filed for a single reporting person.
Adaptive Biotechnologies (ADPT) reported insider transactions by its Chief Commercial Officer, Immune Medicine, Sharon Benzeno. On November 20–21, 2025, she executed multiple stock option exercises and related sales of common stock under a Rule 10b5-1 trading plan adopted on August 18, 2025.
She exercised options covering 133,032, 68,961, 834, 20,834, 49,480, 34,375, 119,809 and 83,145 shares at exercise prices between $3.99 and $12.14 per share, converting them into common stock. She then sold 297,925 shares at a weighted average price of $16.54 and 308,477 shares at a weighted average price of $16.91 in multiple transactions within stated price ranges.
Following these transactions, she directly beneficially owns 296,791 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp (ADPT)11/17/2025, the CFO sold 238 shares of common stock at a price of $14.05 per share. After this transaction, the CFO beneficially owned 269,343 shares of Adaptive Biotechnologies common stock directly.
The company explains that this sale was made solely to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). The transaction was carried out under the issuer’s equity incentive plan, which requires a mandatory "sell to cover" to satisfy tax obligations, so it was not a discretionary trade by the reporting person.
Adaptive Biotechnologies (ADPT) disclosed an insider transaction by its Chief Scientific Officer.
On 11/10/2025, Harlan S. Robins sold 10,000 shares of common stock at a weighted average price of $14.82, with trades ranging from $14.58 to $15.05, pursuant to a Rule 10b5-1 trading plan adopted on August 11, 2025. Following the sale, he beneficially owned 1,269,524 shares held directly.
Adaptive Biotechnologies (ADPT) insider activity: CEO and Chairman Chad M. Robins reported open-market sales of common stock executed under a Rule 10b5-1 trading plan adopted on August 11, 2025. On November 10, he sold 86,161 shares at a weighted average price of $14.73, followed by 1,237 shares at $14.57 on November 11, and 1,867 shares at $15.00 on November 12. After these transactions, he beneficially owned 2,869,975 shares directly. The prices reflect weighted averages across multiple trades within disclosed ranges.
Adaptive Biotechnologies (ADPT) reported stronger Q3 2025 results. Revenue rose to $93.973 million from $46.435 million a year ago, and the company posted net income of $9.545 million (basic and diluted EPS $0.06) versus a prior-year loss. Year-to-date revenue reached $205.295 million with a net loss of $45.878 million.
Growth reflected higher MRD service revenue and a spike in Immune Medicine collaboration revenue, including $33.742 million recognized from the Genentech collaboration. On August 13, 2025, the Genentech Agreement was terminated (effective February 9, 2026); remaining deferred revenue was recognized and the company is no longer eligible for future milestones or royalties.
Cash and cash equivalents were $55.034 million, with $157.735 million in short‑term marketable securities. Deferred revenue decreased to $42.543 million from $82.945 million at year‑end, reflecting revenue recognition. The revenue interest liability, net, was $131.838 million with an effective interest rate of 8.8%. Shares outstanding were 152,665,188 as of October 31, 2025.
Adaptive Biotechnologies (ADPT)
The company notes the information provided under Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed “filed” under the Exchange Act, nor incorporated into Securities Act or Exchange Act filings except by specific reference.
Adaptive Biotechnologies Corporation disclosed developments focused on its Immune Medicine initiatives. The filing notes work on TCR-antigen prediction models to enable new immunology applications and partnerships, and progress toward a pre-clinical data package for its lead T-cell depletion program in autoimmunity. The company also states a fiscal year 2025 Immune Medicine cash burn target of $25–$30 million. The filing references recognition of non-cash revenue from remaining amortization of cash consideration under an agreement. The document is dated August 18, 2025.
FAQ
What is the current stock price of Adaptive Biotechnologies (ADPT)?
What is the market cap of Adaptive Biotechnologies (ADPT)?
